BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) saw strong trading volume on Wednesday . 1,070,141 shares traded hands during trading, an increase of 143% from the previous session’s volume of 440,659 shares.The stock last traded at $3.33 and had previously closed at $3.00.

Several equities research analysts have recently issued reports on the stock. FBR & Co reaffirmed a “buy” rating and set a $6.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, July 6th. Jefferies Group upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Wednesday, June 1st. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, May 9th. Finally, Zacks Investment Research lowered shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 9th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $9.70.

The firm’s 50 day moving average is $2.99 and its 200 day moving average is $3.45. The stock’s market cap is $251.29 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Thursday, May 5th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.08. The firm had revenue of $4.82 million for the quarter, compared to analyst estimates of $5.42 million. The company’s revenue for the quarter was down 29.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.21) EPS. On average, analysts expect that BioCryst Pharmaceuticals Inc. will post ($1.06) EPS for the current year.

Other hedge funds and institutional investors have recently made changes to their positions in the company. Globeflex Capital L P purchased a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at $1,241,000. Jennison Associates LLC increased its position in shares of BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock valued at $13,917,000 after buying an additional 24,014 shares during the period. Finally, Morgan Stanley increased its position in shares of BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock valued at $1,071,000 after buying an additional 12,646 shares during the period.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.